Eli Lilly inks $200M armed antibody pact with ImmunoGen

ImmunoGen ($IMGN) says it's struck a $200 million deal to collaborate with Eli Lilly ($LLY) on developing new armed antibodies. In a filing with the SEC the biotech adds that Lilly will also pay out unspecified royalties on any approved drugs to come out of the pact, which deals with a specific antigen. The company's claim to fame so far rests with the pioneering anticancer technology behind Roche's ($RHHBY) Kadcyla. Filing

Suggested Articles

A patient has died in the global study of AstraZeneca’s COVID-19 vaccine, Brazil’s health authority, Anvisa, announced on Wednesday.

MyoKardia wasn’t looking for a buyout when it started discussing potential partnerships with Bristol Myers Squibb last year.

The patient was hospitalized with febrile neutropenia in the weeks after receiving the drug and died 52 days post-treatment with the CAR-T therapy.